Two complete responses and response rate of 41% for people with synovial sarcoma reported at ASCO in Adaptimmune's phase 2 SPEARHEAD-1 trial

2021-05-20

(Press-News.org) Data will support BLA filing for afamitresgene autoleucel next year - Responses observed across a broad range of antigen expression - Initial safety and durability are encouraging -

PHILADELPHIA, PA., and OXFORDSHIRE, U.K., May 20, 2021 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today. Data will be presented in an oral presentation by Dr. Sandra D'Angelo of the Memorial Sloan Kettering Cancer Center (Abstract #11504) on June 4th.

"Patients are seeing substantial benefit from afami-cel in SPEARHEAD-1 across a broad range of cell doses and levels of MAGE-A4 expression," said Adrian Rawcliffe, Adaptimmune Chief Executive Officer. "We have shown a high response rate and these responses are still evolving in many patients with increasing depths of response over time and encouraging durability. I am confident that SPEARHEAD-1 will support our BLA submission next year and offer a life-changing treatment for people with synovial sarcoma."

"Initial data from SPEARHEAD-1 indicate that afami-cel has the potential to offer people with synovial sarcoma a promising new treatment option where there is currently a great unmet medical need," said Dr. Sandra D'Angelo of the Memorial Sloan Kettering Cancer Center. "As clinicians, we want to be able to provide a treatment regimen that can help offer a better quality of life."

SPEARHEAD-1 data will be presented at the time of the oral presentation scheduled for June 4th during the sarcoma session taking place from 1:30 p.m. to 4:30 p.m. EDT.

Afami-cel is efficacious and well-tolerated in heavily pre treated patients based on initial data At the time of data cut-off (March 29, 2021), 37 patients had received afami-cel (32 with synovial sarcoma, 5 with myxoid/ round cell liposarcoma [MRCLS]) Of the 37 patients who had received afami-cel, 4 patients were pending first efficacy assessment, and 33 had at least one scan as of data cut off (29 with synovial sarcoma, 4 with MRCLS) The overall response rate was 39.3% (13/33), 41.4% (12/29) for synovial sarcoma; 25.0% (1/4) for MRCLS Of the 29 patients with synovial sarcoma with at least one scan, 2 had complete responses (CRs), 10 had partial responses (PRs), 13 had stable disease (SD), 4 had progressive disease (PD) The disease control rate for people with synovial sarcoma was 86.2% (25/29) (defined as either response or stable disease) Of the 4 patients with MRCLS with at least one scan, 1 patient had a partial response, 2 had stable disease, and 1 had progressive disease Objective responses have been reported across a wide range of cell doses and MAGE-A4 antigen expression levels Initial durability data is encouraging, and the median duration of response has not been reached To date, the safety profile of afami-cel has been favorable, with mainly low-grade cytokine release syndrome and tolerable/reversible hematologic toxicities.

Overview of SPEARHEAD-1 trial design SPEARHEAD-1 is a Phase 2, open-label trial for people with advanced synovial sarcoma or MRCLS to evaluate the efficacy, safety, and tolerability of afami-cel. Afami-cel SPEAR T-cells target MAGE-A4+ tumors. MAGE-A4 is highly expressed in synovial sarcoma and MRCLS in the context of HLA A*02. Compelling clinical responses in patients with synovial sarcoma were previously reported with afami-cel in a Phase 1 trial (CTOS 2020).

Approximately 90 patients are planned to be treated: 45 in Cohort 1 and 45 in Cohort 2. Enrollment in Cohort 1 is complete, and Cohort 2 is currently recruiting. The primary efficacy analysis will be for Cohort 1 only, which will be used to support the BLA filing next year. No formal hypothesis testing is planned for Cohort 2. Cohort 2 will strengthen the efficacy and safety database and will aid in descriptive sub group analyses.

Eligible patients were ? 16 and < 75 years, HLA*02 positive with MAGE-A4 expression in ? 30% of tumor cells that were ? 2+ by immunohistochemistry. Eligible patients received afami-cel doses between 1-10 × 109 transduced T-cells after receiving lymphodepleting chemotherapy.

The primary endpoint is overall response rate per RECIST v1.1 by independent review. The primary endpoint will be evaluated using a one-sided exact-based Clopper-Pearson 97.5% confidence interval (CI). If the lower bound of the CI exceeds the response rate reported with historical second line therapy(ies), the trial will have met the pre-specified threshold for demonstrating efficacy.

An independent Data Safety Monitoring Board reviews ongoing safety and benefit:risk during the interventional phase of the trial.

INFORMATION:

About Adaptimmune Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 6, 2021 and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

Adaptimmune Contacts:

Media Relations:

Sébastien Desprez -- VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176
Sebastien.Desprez@adaptimmune.com

Investor Relations:

Juli P. Miller, Ph.D. -- Senior Director, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920
Juli.Miller@adaptimmune.com

ELSE PRESS RELEASES FROM THIS DATE:

Less forest, more species

2021-05-20

Normally, mountain forests are among the most diverse habitats in alpine regions. Yet, as a team from the Alfred Wegener Institute discovered in the Tibetan Plateau, the higher, treeless areas are home to far more species. Their findings, which were just published in the journal Nature Communications, can help to predict how the biodiversity of alpine regions will decline in response to global warming - when the mountain forests spread to higher elevations. As anyone who has ever hiked in the mountains knows, the landscape changes with the elevation. At first, for a long time, you trek uphill through forests, until they open up into the first meadows and pastures, where a wide range of plant species bloom in the spring. Farther up, the landscape becomes more barren. ...

Moon mission delays could increase risks from solar storms

2021-05-20

Planned missions to return humans to the Moon need to hurry up to avoid hitting one of the busiest periods for extreme space weather, according to scientists conducting the most in-depth ever look at solar storm timing. Scientists at the University of Reading studied 150 years of space weather data to investigate patterns in the timing of the most extreme events, which can be extremely dangerous to astronauts and satellites, and even disrupt power grids if they arrive at Earth. The researchers found for the first time that extreme space weather events are more likely to occur early in even-numbered solar cycles, and late in odd-numbered cycles - such as the one just starting. They are also ...

Red meat intake, poor education linked to colorectal cancer

2021-05-20

A new paper in JNCI Cancer Spectrum, published by Oxford University Press, indicates that several non-genetic factors--including greater red meat intake, lower educational attainment, and heavier alcohol use--are associated with an increase in colorectal cancer in people under 50. In the United States, incidence rates of early-onset colorectal cancer have nearly doubled between 1992 and 2013 (from 8.6 to 13.1 per 100,000), with most of this increase due to early-onset cancers of the rectum. Approximately 1 in 10 diagnoses of colorectal cancer in this country occur in people under 50. Researchers ...

Walking in their shoes: Using virtual reality to elicit empathy in healthcare providers

2021-05-20

Philadelphia, May 20, 2021 - Research has shown empathy gives healthcare workers the ability to provide appropriate supports and make fewer mistakes. This helps increase patient satisfaction and enhance patient outcomes, resulting in better overall care. In an upcoming issue of the END ...

New tool factors effects of fossil-fuel emissions on ocean research

2021-05-20

A newly developed tool will allow scientists to better gauge how centuries of fossil fuel emissions could be skewing the data they collect from marine environments. Researchers at the University of Alaska Fairbanks led the effort, which created a way for marine scientists to factor into their results the vast amounts of anthropogenic carbon dioxide that are being absorbed by oceans. Those human-caused carbon sources can muddy research results -- a problem known as the Suess effect -- leading to flawed conclusions about the health and productivity of marine ecosystems. "The ...

Oncotarget: The comprehensive genomic profiling test, GEM ExTra®

2021-05-20

Oncotarget published "Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®" which reported that the authors developed and analytically validated a comprehensive genomic profiling assay, GEM ExTra, for patients with advanced solid tumors that uses Next Generation Sequencing to characterize whole exomes employing a paired tumor-normal subtraction methodology. The assay detects single nucleotide variants, indels, focal copy number alterations, TERT promoter region, as well as tumor mutation burden and microsatellite instability status. Additionally, the assay incorporates ...

Technique uses fluctuations in video pixels to measure energy use of developing embryos

2021-05-20

Scientists have made a major breakthrough in the study of embryonic development and how it can be impacted by external factors such as climate change. Researchers at the University of Plymouth have developed a cutting edge technique which enables them to instantly examine the biological traits and behaviours of developing embryos as an energy signature, rather than focusing on individual characteristics. The method, outlined in a study published in BMC Bioinformatics, is built around timelapse video captured by the researchers of aquatic animals - specifically, the embryos of a freshwater pond snail Radix ...

New FAST discoveries shed light on pulsars

2021-05-20

Using the Five-hundred-meter Aperture Spherical radio Telescope (FAST), a research team led by Prof. HAN Jinlin from National Astronomical Observatories of Chinese Academy of Sciences (NAOC) has discovered 201 pulsars, including many very faint pulsars, 40 millisecond pulsars (MSPs), and 16 pulsars in binaries. These discoveries were published in Research in Astronomy and Astrophysics. Pulsars are compact remnants of the death of bright, massive stars. They have the strongest magnetic field, highest density and fastest rotation of any celestial body in the Universe, and show significant ...

New pan-European research reveals double the concern about mental health impact of Lockdown and associated restrictions than physical inactivity

2021-05-20

Nearly two thirds (61%) expressed concern about their worsening mood in Lockdown and associated restrictions1. 34% said they felt more anxious and 28% felt more depressed during Lockdown and associated restrictions1. Coffee helped lift nearly half (44%) of adult's negative moods in Lockdown and associated restrictions1. A new pan-European survey funded by the Institute for Scientific Information on Coffee exploring the impact of COVID-19 Lockdowns and associated restrictions (in those countries where there has been no Lockdown), has found that nearly two thirds of adults (61%) expressed concern about their worsening mood; two times higher than those concerned about physical inactivity (24%)1. Understanding the effects of COVID-19 restrictions ...

A rapid antigen test for SARS-CoV-2 in saliva

2021-05-20

Scientists from Hokkaido University have shown that an antigen-based test for quantifying SARS-CoV-2 in saliva samples is simple, rapid, and more conducive for mass-screening. More than a year into the COVID-19 pandemic, the RT-PCR test remains the gold standard for detection of the SARS-CoV-2 virus. This method requires trained personnel at every step, from collection of nasopharyngeal swab (NPS) samples to interpretation of the results; in addition, the entire process ranges from 24-48 hours on average. As the virus can be transmitted by an infected person before symptoms ...

Two complete responses and response rate of 41% for people with synovial sarcoma reported at ASCO in Adaptimmune's phase 2 SPEARHEAD-1 trial

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: